$901 Million is the total value of Broadfin Capital, LLC's 64 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 57.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | HORIZON PHARMA PLC | $96,430,000 | -3.4% | 5,959,819 | +8.3% | 10.71% | +19.7% |
| HRTX | Buy | HERON THERAPEUTICS INC | $51,085,000 | +4.0% | 3,899,587 | +36.8% | 5.67% | +28.9% |
| PETX | Buy | ARATANA THERAPEUTICS INC | $26,533,000 | -8.1% | 3,695,442 | +19.7% | 2.95% | +13.8% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $26,476,000 | -23.1% | 1,510,316 | +4.4% | 2.94% | -4.7% |
| ENDP | Buy | ENDO INTL PLC | $25,694,000 | -12.3% | 1,560,038 | +7.3% | 2.85% | +8.6% |
| REPH | Buy | RECRO PHARMA INC | $24,987,000 | +15.4% | 3,100,086 | +26.5% | 2.77% | +42.9% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDadr | $23,472,000 | +70.0% | 647,500 | +115.8% | 2.61% | +110.7% |
| ARLZ | Buy | ARALEZ PHARMACEUTICALS INC | $21,131,000 | -1.1% | 4,791,590 | +8.7% | 2.35% | +22.4% |
| GNMX | New | AEVI GENOMIC MEDICINE INC | $17,458,000 | – | 3,370,306 | +100.0% | 1.94% | – |
| NVLNF | New | NOVELION THERAPEUTICS INC | $16,407,000 | – | 1,948,554 | +100.0% | 1.82% | – |
| MDCO | Buy | MEDICINES CO | $14,811,000 | +53.5% | 436,400 | +70.7% | 1.64% | +90.3% |
| VCYT | New | VERACYTE INC | $13,841,000 | – | 1,788,266 | +100.0% | 1.54% | – |
| ACOR | Buy | ACORDA THERAPEUTICS INC | $12,110,000 | -4.1% | 644,153 | +6.5% | 1.34% | +18.7% |
| DRRX | Buy | DURECT CORP | $11,398,000 | +28.2% | 8,506,229 | +33.0% | 1.26% | +58.7% |
| BDSI | Buy | BIODELIVERY SCIENCES INTL IN | $9,448,000 | -32.6% | 5,398,794 | +4.0% | 1.05% | -16.5% |
| BCR | New | BARD C R INC | $9,031,000 | – | 40,200 | +100.0% | 1.00% | – |
| New | EGALET CORPnote 5.500% 4/0 | $8,923,000 | – | 10,000,000 | +100.0% | 0.99% | – | |
| ZBH | New | ZIMMER BIOMET HLDGS INC | $8,617,000 | – | 83,500 | +100.0% | 0.96% | – |
| ELGX | Buy | ENDOLOGIX INC | $8,580,000 | -16.2% | 1,500,000 | +87.5% | 0.95% | +3.8% |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $6,947,000 | -19.7% | 2,894,581 | +74.7% | 0.77% | -0.5% |
| IDRA | Buy | IDERA PHARMACEUTICALS INC | $6,642,000 | +6.9% | 4,427,745 | +82.4% | 0.74% | +32.3% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $5,854,000 | +206.3% | 562,875 | +237.3% | 0.65% | +280.1% |
| MDT | New | MEDTRONIC PLC | $5,342,000 | – | 75,000 | +100.0% | 0.59% | – |
| GKOS | New | GLAUKOS CORP | $4,847,000 | – | 141,300 | +100.0% | 0.54% | – |
| ADHD | Buy | ALCOBRA LTD | $4,320,000 | -14.6% | 2,057,106 | +0.5% | 0.48% | +6.0% |
| NVET | Buy | NEXVET BIOPHARMA PUB LTD CO | $4,205,000 | -0.4% | 1,127,200 | +10.8% | 0.47% | +23.5% |
| New | PERNIX THERAPEUTICS HLDGS INdbcv 4.250% 4/0 | $3,565,000 | – | 15,500,000 | +100.0% | 0.40% | – | |
| MDWD | Buy | MEDIWOUND LTD | $2,899,000 | -29.1% | 633,102 | +19.2% | 0.32% | -12.0% |
| PTN | New | PALATIN TECHNOLOGIES INC | $1,943,000 | – | 3,846,154 | +100.0% | 0.22% | – |
| CGNT | New | COGENTIX MED INC | $1,515,000 | – | 753,773 | +100.0% | 0.17% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.